Market News & Trends
TxCell Receives Approval for Phase I/II Clinical Trial Extension
TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, recently announced the approval…
Critical Outcome Technologies Initiates Development of Optimal Oral Oncology Formulation
Critical Outcome Technologies Inc. recently announced it has initiated a project to develop an optimal oral formulation of COTI-2. This lead oncology product has demonstrated…
5/24/2011
Sartorius Stedim Biotech & RAUMEDIC Sign Partnership Agreement Sartorius Stedim Biotech (SSB), an international leading pharma and biotech supplier, and RAUMEDIC, a leading worldwide OEM…
5/10/2011
QRxPharma Completes Patient Enrolment of Phase III Comparative Safety Study QRxPharma Limited recently announced it has completed patient enrolment for Study 022, a Phase III…
Avantor Performance Materials to Acquire POCH S.A.
Avantor Performance Materials announced a definitive agreement to acquire POCH S.A. from Kulczyk. Completion of the sale is dependent upon obtaining the necessary clearance from…
Axcan & Eurand Announce Name Change
Axcan Intermediate Holdings Inc. recently announced it is changing its name to Aptalis Pharma. The rebranding follows the recently completed combination of two specialty pharma companies…
MicroDose Therapeutx Announces Development Milestone Triggering Payment Under Respiratory Collaboration
MicroDose Therapeutx, Inc. recently announced that a development milestone in its collaboration with Novartis has been achieved, triggering a payment under the multi-product development and…
Nabi Biopharmaceuticals Completes Final Milestone; $5 Million Payment Received
Nabi Biopharmaceuticals recently announced it has completed the Phase I trial for two of the PentaStaph antigens that began in December 2009. Completion of this…
Novozymes Biopharma Collaborates With University to Tailor the Half-Lives of Proteins
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, recently unveiled its enhanced next-generation albumin technology, which was developed in collaboration with the…
QRxPharma Completes Patient Enrolment of Phase III Comparative Safety Study
QRxPharma Limited recently announced it has completed patient enrolment for Study 022, a Phase III trial comparing the tolerability and safety profile of MoxDuo IR…
Gerresheimer Manufactures Insulin Pen for Big Pharma Company
Gerresheimer AG has recently commenced the commercial production of the ClikSTAR® insulin pens for sanofi-aventis. Medical plastic systems, such as insulin pens, will be increasingly…
Gilead & MicroDose Therapeutx Announce License & Collaboration Agreement
Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. recently announced they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization…
Precision NanoSystems & Alnylam Form New Delivery Collaboration
Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, recently announced the two companies have formed an exclusive collaboration focused on the…
Avantor Certifies All Doe & Ingalls Sites Under Certified Excipient Distributor Program
Avantor Performance Materials (formerly Mallinckrodt Baker) recently announced that Doe & Ingalls, a national chemical services provider and Avantor distributor, is the first distributor to…
Baxter Acquires Specialty Pharmaceutical Company
Baxter International Inc. recently announced it has entered into a definitive agreement to acquire privately held Prism Pharmaceuticals, Inc., a specialty pharmaceutical company based in…
Brainlab & SurgiVision Announce Strategic Alliance
Brainlab AG and SurgiVision, Inc. recently announced a collaboration aimed at integrating SurgiVision's ClearPoint product line with Brainlab's iMRI product line, with particular focus on…
4/26/2011
Precision NanoSystems & Alnylam Form New Delivery Collaboration Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, recently announced the two companies…
4/12/2011
IBM & the Institute of Bioengineering & Nanotechnology Find Breakthrough TreatmentResearchers from IBM and the Institute of Bioengineering and Nanotechnology recently discovered a nanomedicine breakthrough…
Antares Pharma Announces NDA Accepted for Filing
Antares Pharma, Inc. recently announced the NDA for Anturol Gel in patients with overactive bladder (OAB) was accepted for filing for review by the US…
Aptar Pharma Registers Contract Test Laboratories With US FDA
Aptar Pharma's French manufacturing sites in Le Vaudreuil and Val-de-Reuil have been registered as Contract Test Laboratories for extractables testing with the US FDA. A…
